These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 33142025)

  • 1. The impact of a cascade testing video on recipients' knowledge, cognitive message processing, and affective reactions: A formative evaluation.
    Aeilts AM; Carpenter KM; Hovick SR; Byrne L; Shoben AB; Senter L
    J Genet Couns; 2021 Jun; 30(3):656-664. PubMed ID: 33142025
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BRCAShare-Assessment of an animated digital message for intrafamilial communication of pathogenic variant positive test results: A feasibility study.
    Aeilts AM; Carpenter KM; Hovick SR; Byrne L; Shoben AB; Senter L
    J Genet Couns; 2023 Apr; 32(2):475-485. PubMed ID: 36426678
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cascade testing in Italian Hereditary Breast Ovarian Cancer families: a missed opportunity for cancer prevention?
    Trevisan L; Godino L; Battistuzzi L; Innella G; Luppi E; Buzzatti G; Gismondi V; Blondeaux E; Bonelli LA; Turchetti D; Varesco L
    Fam Cancer; 2024 Jun; 23(2):197-207. PubMed ID: 37968543
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Psychosocial barriers and facilitators for cascade genetic testing in hereditary breast and ovarian cancer: a scoping review.
    Afaya A; Kim SW; Park HS; Lim MC; Jung MS; Nam EJ; Park JS; Jeong J; Ryu JM; Kim J; Kim J; Kim M; Jin J; Han J; Kim SY; Park SY; Katapodi MC; Kim S;
    Fam Cancer; 2024 Jun; 23(2):121-132. PubMed ID: 38662264
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cancer Predisposition Cascade Screening for Hereditary Breast/Ovarian Cancer and Lynch Syndromes in Switzerland: Study Protocol.
    Katapodi MC; Viassolo V; Caiata-Zufferey M; Nikolaidis C; Bührer-Landolt R; Buerki N; Graffeo R; Horváth HC; Kurzeder C; Rabaglio M; Scharfe M; Urech C; Erlanger TE; Probst-Hensch N; Heinimann K; Heinzelmann-Schwarz V; Pagani O; Chappuis PO
    JMIR Res Protoc; 2017 Sep; 6(9):e184. PubMed ID: 28931501
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The uptake of presymptomatic genetic testing in hereditary breast-ovarian cancer and Lynch syndrome: a systematic review of the literature and implications for clinical practice.
    Menko FH; Ter Stege JA; van der Kolk LE; Jeanson KN; Schats W; Moha DA; Bleiker EMA
    Fam Cancer; 2019 Jan; 18(1):127-135. PubMed ID: 29846880
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BRCA1 and BRCA2 mutational profile and prevalence in hereditary breast and ovarian cancer (HBOC) probands from Southern Brazil: Are international testing criteria appropriate for this specific population?
    Alemar B; Gregório C; Herzog J; Matzenbacher Bittar C; Brinckmann Oliveira Netto C; Artigalas O; Schwartz IVD; Coffa J; Alves Camey S; Weitzel J; Ashton-Prolla P
    PLoS One; 2017; 12(11):e0187630. PubMed ID: 29161300
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Using a Tailored Digital Health Intervention for Family Communication and Cascade Genetic Testing in Swiss and Korean Families With Hereditary Breast and Ovarian Cancer: Protocol for the DIALOGUE Study.
    Kim S; Aceti M; Baroutsou V; Bürki N; Caiata-Zufferey M; Cattaneo M; Chappuis PO; Ciorba FM; Graffeo-Galbiati R; Heinzelmann-Schwarz V; Jeong J; Jung MM; Kim SW; Kim J; Lim MC; Ming C; Monnerat C; Park HS; Park SH; Pedrazzani CA; Rabaglio M; Ryu JM; Saccilotto R; Wieser S; Zürrer-Härdi U; Katapodi MC
    JMIR Res Protoc; 2021 Jun; 10(6):e26264. PubMed ID: 34114954
    [TBL] [Abstract][Full Text] [Related]  

  • 9. "It wasn't just for me": Motivations and implications of genetic testing for women at a low risk of hereditary breast and ovarian cancer syndrome.
    Gill G; Beard C; Storey K; Taylor S; Sexton A
    Psychooncology; 2020 Aug; 29(8):1303-1311. PubMed ID: 32497346
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanisms to increase cascade testing in hereditary breast and ovarian cancer: Impact of introducing standardized communication aids into genetic counseling.
    Garcia C; Sullivan MW; Lothamer H; Harrison KM; Chatfield L; Thomas MH; Modesitt SC
    J Obstet Gynaecol Res; 2020 Sep; 46(9):1835-1841. PubMed ID: 32656916
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Barriers to completion of cascade genetic testing: how can we improve the uptake of testing for hereditary breast and ovarian cancer syndrome?
    Kahn RM; Ahsan MD; Chapman-Davis E; Holcomb K; Nitecki R; Rauh-Hain JA; Fowlkes RK; Tubito F; Pires M; Christos PJ; Tkachuk K; Krinsky H; Sharaf RN; Offit K; Lipkin S; Frey MK
    Fam Cancer; 2023 Apr; 22(2):127-133. PubMed ID: 36207653
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Communication with close and distant relatives in the context of genetic testing for hereditary breast and ovarian cancer in cancer patients.
    Claes E; Evers-Kiebooms G; Boogaerts A; Decruyenaere M; Denayer L; Legius E
    Am J Med Genet A; 2003 Jan; 116A(1):11-9. PubMed ID: 12476445
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A clinically structured and partnered approach to genetic testing in Trinidadian women with breast cancer and their families.
    Donenberg T; George S; Ali J; Bravo G; Hernandez K; Sookar N; Ashing KT; Narod SA; Akbari MR; Hurley J
    Breast Cancer Res Treat; 2019 Apr; 174(2):469-477. PubMed ID: 30515680
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Women's experiences of undergoing BRCA1 and BRCA2 testing: organisation of the German Hereditary Breast and Ovarian Cancer Consortium Survey and Preliminary Data from Münster.
    Nippert I; Schlegelberger B;
    Community Genet; 2003; 6(4):249-58. PubMed ID: 15331871
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Statewide Retrospective Review of Familial Pancreatic Cancer in Delaware, and Frequency of Genetic Mutations in Pancreatic Cancer Kindreds.
    Catts ZA; Baig MK; Milewski B; Keywan C; Guarino M; Petrelli N
    Ann Surg Oncol; 2016 May; 23(5):1729-35. PubMed ID: 26727920
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The uptake of predictive DNA testing in 40 families with a pathogenic BRCA1/BRCA2 variant. An evaluation of the proband-mediated procedure.
    Menko FH; Jeanson KN; Bleiker EMA; van Tiggelen CWM; Hogervorst FBL; Ter Stege JA; Ait Moha D; van der Kolk LE
    Eur J Hum Genet; 2020 Aug; 28(8):1020-1027. PubMed ID: 32300191
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exploring family communication preferences in hereditary breast and ovarian cancer and Lynch syndrome: a national Canadian survey.
    Burke K; Dawson L; Hodgkinson K; Wilson BJ; Etchegary H
    J Community Genet; 2024 Aug; 15(4):387-400. PubMed ID: 39046652
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BRCA1/2 testing in hereditary breast and ovarian cancer families II: impact on relationships.
    McInerney-Leo A; Biesecker BB; Hadley DW; Kase RG; Giambarresi TR; Johnson E; Lerman C; Struewing JP
    Am J Med Genet A; 2005 Mar; 133A(2):165-9. PubMed ID: 15633195
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differences between women who pursued genetic testing for hereditary breast and ovarian cancer and their at-risk relatives who did not.
    Katapodi MC; Northouse L; Pierce P; Milliron KJ; Liu G; Merajver SD
    Oncol Nurs Forum; 2011 Sep; 38(5):572-81. PubMed ID: 21875844
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Actionability of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Risk Assessment.
    Desmond A; Kurian AW; Gabree M; Mills MA; Anderson MJ; Kobayashi Y; Horick N; Yang S; Shannon KM; Tung N; Ford JM; Lincoln SE; Ellisen LW
    JAMA Oncol; 2015 Oct; 1(7):943-51. PubMed ID: 26270727
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.